Outsourcing

The company expanded its topicals capacity with an investment in the Becomix RW30 model homogenizer.

PharmTech sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.

Investment at SGS’s Mississauga, Canada facility provides for analysis of molecular interactions in real time.

Growth may be slowing, but outsourcing activity remains healthy.

Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how to report quality metrics to FDA.

With deadlines only a few years away, some companies have not started serialization programs, while others are taking a tactical, short-term approach, losing out on potential business benefits.

MilliporeSigma, the North American life-sciences business of Germany’s Merck KGaA, added a 2000-L single-use bioreactor to its facility in Massachusetts.

WellSpring Pharma formed a strategic partnership with IDT Australia and invested $3 million in new equipment.

A program for calibration and routine testing of weighing instruments ensures accurate results.

Transferring the manufacturing of a drug from one scale to another or between manufacturing sites presents both technical and business challenges.

Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems.

Demand is driving expansion and consolidation of formulation and clinical trial materials services.

At DCAT's annual meeting, Bill Downey, president of the market research firm High Tech Business Decisions, summarized results from its latest survey on biopharmaceutical outsourcing.

Collaboration will provide for unified development and manufacture of antibody drug conjugates.

Hovione will operate a commercial-scale continuous manufacturing facility in New Jersey as part of an agreement with Vertex Pharmaceuticals.

Global economic and political uncertainty could slow bio/pharma development activity.

The pharma outsourcing market starts 2016 with expansions, acquisitions, and new offerings.

As specialty API outsourcing grows, manufacturers and contract development and manufacturing organizations are investing for the long haul.

Data integrity has become a more serious compliance problem at pharmaceutical manufacturing plants throughout the world.

The author lists five key areas to consider when selecting a CDMO to develop highly potent formulations.

The authors provide their perspectives on shipping validation.

Cirrus Pharmaceuticals will launch services for manufacturing cGMP materials for early-phase clinical trials at its Raleigh-Durham, NC facility.

Recipharm acquires Mitim, adding scale and technology in injectable beta lactams.

PharmSource report addresses how the opportunity for antibody drug conjugates measures up to the bio/pharma industry’s expectations.

Smart glasses enhance remote troubleshooting and process management for pharmaceutical manufacturing.